30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Aduro Biotech Inc (ADRO)

Track

The most recent insider trading activity occurred on August 1, 2023, with a SELL transaction by Chief Scientific Officer Andrew James King. Prior to this, several planned and proposed sales were noted in April and May 2023, involving executives such as President and CEO Eric Dobmeier and Officer/Director Eric Dobmeier. Significant sell transactions were also recorded in March and February 2023 by Jerel Davis and other officers.
Stock chart
Ticker: ADRO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
King Andrew James
Chief Scientific Officer
1 sale — total 45,586 USD
Sale 1 Aug 2023
Value US$4,344,381.22 | Price 55.25 | Shares 78,722
Planned sale 30 May 2023
Value US$2,599,084.07 | Price 366.75 | Shares 9,497
Planned sale 24 Apr 2023
Value US$513,527.84 | Price 21.58 | Shares 23,800
Proposed sale 24 Apr 2023
Value US$540,237.50 | Price 21.61 | Shares 25,000
Sale 17 Apr 2023
Value US$6,138,223.07 | Price 20.75 | Shares 295,808
Planned sale 4 Apr 2023
Value US$21,261.24 | Price 23.01 | Shares 924
Planned sale 3 Apr 2023
Value US$116,717.50 | Price 23.34 | Shares 5,000
Sale 1 Mar 2023
Value US$836,085.25 | Price 22.75 | Shares 36,751
Sale 1 Mar 2023
Value US$2,803,914.75 | Price 22.75 | Shares 123,249
Sale 1 Mar 2023
Value US$5,460,000.00 | Price 22.75 | Shares 240,000
Sale 10 Feb 2023
Value US$56,806.41 | Price 23.75 | Shares 2,392
Sale 10 Feb 2023
Value US$20,352.46 | Price 23.75 | Shares 857
Sale 10 Feb 2023
Value US$87,869.45 | Price 23.75 | Shares 3,700
Sale 10 Feb 2023
Value US$192,291.60 | Price 23.75 | Shares 8,097
Sale 31 Jan 2023
Value US$80,069.06 | Price 24.68 | Shares 3,244
Sale 31 Jan 2023
Value US$112,699.84 | Price 24.68 | Shares 4,566
Sale 31 Jan 2023
Value US$71,356.53 | Price 24.68 | Shares 2,891
Sale 31 Jan 2023
Value US$189,756.75 | Price 24.68 | Shares 7,688
Planned sale 30 Jan 2023
Value US$613,612.50 | Price 24.54 | Shares 25,000
Planned sale 3 Jan 2023
Value US$258,183.00 | Price 25.82 | Shares 10,000
Planned sale 13 Dec 2022
Value US$250,005.00 | Price 25.00 | Shares 10,000
Planned sale 1 Dec 2022
Value US$669,351.00 | Price 22.31 | Shares 30,000
Sale 1 Dec 2022
Value US$128,601.76 | Price 22.29 | Shares 5,770
Planned sale 7 Nov 2022
Value US$221,642.00 | Price 22.16 | Shares 10,000
Sale 6 Oct 2022
Value US$144,933.12 | Price 19.69 | Shares 7,360
Sale 6 Oct 2022
Value US$70,044.44 | Price 19.69 | Shares 3,557
Buy 2 Sep 2022
Value US$6,360.00 | Price 21.20 | Shares 300
Buy 2 Sep 2022
Value US$205,834.00 | Price 21.22 | Shares 9,700
Planned sale 4 Aug 2022
Value US$100,000.00 | Price 20.00 | Shares 5,000
Planned sale 11 Jul 2022
Value US$90,468.00 | Price 18.09 | Shares 5,000
Buy 27 May 2022
Value US$7,980,000.00 | Price 14.00 | Shares 570,000
Buy 25 May 2022
Value US$65,147.50 | Price 13.03 | Shares 5,000
Planned sale 11 Apr 2022
Value US$76,812.00 | Price 15.36 | Shares 5,000
Planned sale 18 Feb 2022
Value US$32,500.00 | Price 13.00 | Shares 2,500
Sale 11 Feb 2022
Value US$11,403.37 | Price 12.74 | Shares 895
Sale 11 Feb 2022
Value US$30,463.97 | Price 12.74 | Shares 2,391
Sale 11 Feb 2022
Value US$31,827.27 | Price 12.74 | Shares 2,498
Sale 11 Feb 2022
Value US$47,586.89 | Price 12.74 | Shares 3,735
Planned sale 10 Feb 2022
Value US$33,275.00 | Price 13.31 | Shares 2,500
Planned sale 3 Jan 2022
Value US$1,472,018.40 | Price 16.00 | Shares 92,000
Planned sale 3 Jan 2022
Value US$4,928,061.60 | Price 16.00 | Shares 308,000
Planned sale 3 Jan 2022
Value US$9,600,120.00 | Price 16.00 | Shares 600,000
Planned sale 3 Jan 2022
Value US$1,472,018.40 | Price 16.00 | Shares 92,000
Planned sale 3 Jan 2022
Value US$4,928,061.60 | Price 16.00 | Shares 308,000
Planned sale 3 Jan 2022
Value US$9,600,120.00 | Price 16.00 | Shares 600,000
Buy 15 Nov 2021
Value US$17,010,000.00 | Price 14.00 | Shares 1,215,000
Planned sale 10 Nov 2021
Value US$96,440.40 | Price 15.48 | Shares 6,230
Planned sale 9 Nov 2021
Value US$67,659.50 | Price 13.53 | Shares 5,000
Planned sale 8 Nov 2021
Value US$208,937.72 | Price 15.17 | Shares 13,770
Planned sale 5 Nov 2021
Value US$70,000.00 | Price 14.00 | Shares 5,000
Planned sale 5 Nov 2021
Value US$210,000.00 | Price 14.00 | Shares 15,000
Planned sale 16 Jun 2021
Value US$326,968.00 | Price 16.35 | Shares 20,000
Buy 14 May 2021
Value US$14,440.00 | Price 14.44 | Shares 1,000
Buy 9 Dec 2020
Value US$26,150.00 | Price 13.08 | Shares 2,000
Buy 8 Dec 2020
Value US$26,483.40 | Price 13.24 | Shares 2,000
Buy 23 Nov 2020
Value US$12,698.78 | Price 13.67 | Shares 929
Buy 20 Nov 2020
Value US$7,816.99 | Price 13.69 | Shares 571
Buy 19 Nov 2020
Value US$6,750.00 | Price 13.50 | Shares 500
Buy 11 Nov 2020
Value US$34,375.00 | Price 13.75 | Shares 2,500
Buy 10 Nov 2020
Value US$27,720.00 | Price 13.86 | Shares 2,000
Sale 15 Sep 2020
Value US$5,730.99 | Price 2.39 | Shares 2,396
Sale 15 Sep 2020
Value US$29,585.41 | Price 2.39 | Shares 12,369
Sale 15 Sep 2020
Value US$77,691.30 | Price 2.39 | Shares 32,481
Sale 7 Aug 2020
Value US$9,036.41 | Price 2.55 | Shares 3,538
Sale 7 Aug 2020
Value US$20,307.65 | Price 2.55 | Shares 7,951
Sale 7 Aug 2020
Value US$20,307.65 | Price 2.55 | Shares 7,951
Sale 25 Feb 2020
Value US$23,953.51 | Price 3.51 | Shares 6,823
Sale 3 Jan 2020
Value US$87,108.13 | Price 1.19 | Shares 73,311
Sale 12 Dec 2019
Value US$474.63 | Price 1.16 | Shares 408
Sale 12 Dec 2019
Value US$2,549.95 | Price 1.16 | Shares 2,192
Sale 12 Dec 2019
Value US$6,859.98 | Price 1.16 | Shares 5,897
Planned sale 12 Dec 2019
Value US$1,470.41 | Price 1.16 | Shares 1,264
Sale 13 Sep 2019
Value US$828.07 | Price 1.31 | Shares 634
Sale 13 Sep 2019
Value US$23,450.86 | Price 1.31 | Shares 17,959
Sale 13 Sep 2019
Value US$1,439.32 | Price 1.31 | Shares 1,102
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-08-01 2023-08-01 S Sale
King Andrew James

Chief Scientific Officer

Officer
78,722 +1.4%
55.25
US$4,344,381 		78,722 +1.4% 55.25 US$4,344,381
2023-05-31 2023-05-30 PlS Planned sale
2.8
Greenman William Mariner
Non-Executive Director
9,497 -42.7%
366.75
US$2,599,084 		9,497 -42.7% 366.75 US$2,599,084
2023-04-26 2023-04-24 PlS Planned sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
11,581 +27.3%
174.40
US$3,272,134 		11,581 +27.3% 174.40 US$3,272,134
2023-04-24 2023-04-24 PrS Proposed sale
3.6
ERIC DOBMEIER

Officer; Director

Executive Director
25,000
21.61
US$540,238 		25,000 21.61 US$540,238
2023-04-19 2023-04-17 S Sale
2.2
Jerel Davis
Non-Executive Director
295,808 -40.0%
20.75
US$6,138,223 		295,808 -40.0% 20.75 US$6,138,223
2023-04-04 2023-04-04 PlS Planned sale
Krishnan Mahesh
Non-Executive Director
924 -42.0%
23.01
US$21,261 		924 -42.0% 23.01 US$21,261
2023-04-05 2023-04-03 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -22.7%
23.34
US$116,718 		5,000 -22.7% 23.34 US$116,718
2023-03-03 2023-03-01 S Sale
2.2
Jerel Davis
Non-Executive Director
36,751 -14.8%
22.75
US$836,085 		36,751 -14.8% 22.75 US$836,085
2023-03-03 2023-03-01 S Sale
2.2
Jerel Davis
Non-Executive Director
123,249 -14.6%
22.75
US$2,803,915 		123,249 -14.6% 22.75 US$2,803,915
2023-03-03 2023-03-01 S Sale
2.2
Jerel Davis
Non-Executive Director
240,000 -10.2%
22.75
US$5,460,000 		240,000 -10.2% 22.75 US$5,460,000
2023-02-15 2023-02-10 S Sale
King Andrew James

Chief Scientific Officer

Officer
2,392 -10.9%
23.75
US$56,806 		2,392 -10.9% 23.75 US$56,806
2023-02-15 2023-02-10 S Sale
3.3
BJERKHOLT ERIC

Chief Financial Officer

Officer
857 -2.2%
23.75
US$20,352 		857 -2.2% 23.75 US$20,352
2023-02-15 2023-02-10 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
3,700 -2.4%
23.75
US$87,869 		3,700 -2.4% 23.75 US$87,869
2023-02-15 2023-02-10 S Sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
8,097 -2.6%
23.75
US$192,292 		8,097 -2.6% 23.75 US$192,292
2023-02-02 2023-01-31 S Sale
King Andrew James

Chief Scientific Officer

Officer
3,244 -17.7%
24.68
US$80,069 		3,244 -17.7% 24.68 US$80,069
2023-02-02 2023-01-31 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
4,566 -3.0%
24.68
US$112,700 		4,566 -3.0% 24.68 US$112,700
2023-02-02 2023-01-31 S Sale
3.3
BJERKHOLT ERIC

Chief Financial Officer

Officer
2,891 -7.2%
24.68
US$71,357 		2,891 -7.2% 24.68 US$71,357
2023-02-01 2023-01-31 S Sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
7,688 -2.6%
24.68
US$189,757 		7,688 -2.6% 24.68 US$189,757
2023-02-01 2023-01-30 PlS Planned sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
25,000 -8.4%
24.54
US$613,612 		25,000 -8.4% 24.54 US$613,612
2023-01-04 2023-01-03 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
10,000 -50.0%
25.82
US$258,183 		10,000 -50.0% 25.82 US$258,183
2022-12-15 2022-12-13 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
10,000 -6.5%
25.00
US$250,005 		10,000 -6.5% 25.00 US$250,005
2022-12-02 2022-12-01 PlS Planned sale
3.6
DOBMEIER ERIC

President, CEO

Executive Director
30,000 -11.0%
22.31
US$669,351 		30,000 -11.0% 22.31 US$669,351
2022-12-02 2022-12-01 S Sale
3.3
BJERKHOLT ERIC

Chief Financial Officer

Officer
5,770 -14.9%
22.29
US$128,602 		5,770 -14.9% 22.29 US$128,602
2022-11-09 2022-11-07 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
10,000 -6.5%
22.16
US$221,642 		10,000 -6.5% 22.16 US$221,642
2022-10-11 2022-10-06 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
7,360 -4.9%
19.69
US$144,933 		7,360 -4.9% 19.69 US$144,933
2022-10-11 2022-10-06 S Sale
King Andrew James

Chief Scientific Officer

Officer
3,557 -22.2%
19.69
US$70,044 		3,557 -22.2% 19.69 US$70,044
2022-09-06 2022-09-02 B Purchase
Thomas Dolca
Non-Executive Director
300 +3.1%
21.20
US$6,360 		300 +3.1% 21.20 US$6,360
2022-09-06 2022-09-02 B Purchase
Thomas Dolca
Non-Executive Director
9,700 +inf%
21.22
US$205,834 		9,700 +inf% 21.22 US$205,834
2022-08-05 2022-08-04 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -45.9%
20.00
US$100,000 		5,000 -45.9% 20.00 US$100,000
2022-07-13 2022-07-11 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -45.9%
18.09
US$90,468 		5,000 -45.9% 18.09 US$90,468
2022-06-01 2022-05-27 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
570,000 +12.4%
14.00
US$7,980,000 		570,000 +12.4% 14.00 US$7,980,000
2022-05-27 2022-05-25 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
5,000 +2.5%
13.03
US$65,148 		5,000 +2.5% 13.03 US$65,148
2022-04-13 2022-04-11 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -45.9%
15.36
US$76,812 		5,000 -45.9% 15.36 US$76,812
2022-02-23 2022-02-18 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
2,500 -29.8%
13.00
US$32,500 		2,500 -29.8% 13.00 US$32,500
2022-02-14 2022-02-11 S Sale
3.3
BJERKHOLT ERIC

Chief Financial Officer

Officer
895 -3.9%
12.74
US$11,403 		895 -3.9% 12.74 US$11,403
2022-02-14 2022-02-11 S Sale
Glicklich Alan

Chief Medical Officer

Officer
2,391 -23.3%
12.74
US$30,464 		2,391 -23.3% 12.74 US$30,464
2022-02-14 2022-02-11 S Sale
King Andrew James

Chief Scientific Officer

Officer
2,498 -22.9%
12.74
US$31,827 		2,498 -22.9% 12.74 US$31,827
2022-02-14 2022-02-11 S Sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
3,735 -2.6%
12.74
US$47,587 		3,735 -2.6% 12.74 US$47,587
2022-02-11 2022-02-10 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
2,500 -37.9%
13.31
US$33,275 		2,500 -37.9% 13.31 US$33,275
2022-01-05 2022-01-03 PlS Planned sale
Versant Venture Capital VII, L.P.
Large shareholder
92,000 -14.3%
16.00
US$1,472,018 		92,000 -14.3% 16.00 US$1,472,018
2022-01-05 2022-01-03 PlS Planned sale
Versant Venture Capital VII, L.P.
Large shareholder
308,000 -14.2%
16.00
US$4,928,062 		308,000 -14.2% 16.00 US$4,928,062
2022-01-05 2022-01-03 PlS Planned sale
Versant Venture Capital VII, L.P.
Large shareholder
600,000 -14.2%
16.00
US$9,600,120 		600,000 -14.2% 16.00 US$9,600,120
2022-01-05 2022-01-03 PlS Planned sale
2.2
Jerel Davis
Non-Executive Director Large shareholder
92,000 -14.3%
16.00
US$1,472,018 		92,000 -14.3% 16.00 US$1,472,018
2022-01-05 2022-01-03 PlS Planned sale
2.2
Jerel Davis
Non-Executive Director Large shareholder
308,000 -14.2%
16.00
US$4,928,062 		308,000 -14.2% 16.00 US$4,928,062
2022-01-05 2022-01-03 PlS Planned sale
2.2
Jerel Davis
Non-Executive Director Large shareholder
600,000 -14.2%
16.00
US$9,600,120 		600,000 -14.2% 16.00 US$9,600,120
2021-11-17 2021-11-15 B Purchase
3.6
AKKARAJU SRINIVAS
Non-Executive Director
1,215,000 +36.0%
14.00
US$17,010,000 		1,215,000 +36.0% 14.00 US$17,010,000
2021-11-12 2021-11-10 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
6,230 -4.4%
15.48
US$96,440 		6,230 -4.4% 15.48 US$96,440
2021-11-12 2021-11-09 PlS Planned sale
King Andrew James

Chief Scientific Officer

Officer
5,000 -55.0%
13.53
US$67,660 		5,000 -55.0% 13.53 US$67,660
2021-11-09 2021-11-08 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
13,770 -8.9%
15.17
US$208,938 		13,770 -8.9% 15.17 US$208,938
2021-11-09 2021-11-05 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
5,000 -3.1%
14.00
US$70,000 		5,000 -3.1% 14.00 US$70,000
2021-11-09 2021-11-05 PlS Planned sale
0.9
Frohlich Tom

Chief Operating Officer

Officer
15,000 -8.6%
14.00
US$210,000 		15,000 -8.6% 14.00 US$210,000
2021-06-17 2021-06-16 PlS Planned sale
Glicklich Alan

Chief Medical Officer

Officer
20,000 -100.0%
16.35
US$326,968 		20,000 -100.0% 16.35 US$326,968
2021-05-18 2021-05-14 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
1,000 +1.3%
14.44
US$14,440 		1,000 +1.3% 14.44 US$14,440
2020-12-10 2020-12-09 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,000 +3.6%
13.08
US$26,150 		2,000 +3.6% 13.08 US$26,150
2020-12-10 2020-12-08 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,000 +3.8%
13.24
US$26,483 		2,000 +3.8% 13.24 US$26,483
2020-11-23 2020-11-23 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
929 +1.8%
13.67
US$12,699 		929 +1.8% 13.67 US$12,699
2020-11-23 2020-11-20 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
571 +1.1%
13.69
US$7,817 		571 +1.1% 13.69 US$7,817
2020-11-23 2020-11-19 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
500 +1.0%
13.50
US$6,750 		500 +1.0% 13.50 US$6,750
2020-11-13 2020-11-11 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,500 +5.2%
13.75
US$34,375 		2,500 +5.2% 13.75 US$34,375
2020-11-13 2020-11-10 B Purchase
3.6
DOBMEIER ERIC

President, CEO

Executive Director
2,000 +4.3%
13.86
US$27,720 		2,000 +4.3% 13.86 US$27,720
2020-09-17 2020-09-15 S Sale
Ferber Celeste

SVP, GC and Secretary

Officer
2,396 -5.8%
2.39
US$5,731 		2,396 -5.8% 2.39 US$5,731
2020-09-17 2020-09-15 S Sale
Templeman Blaine

Chief Legal Officer

Officer
12,369 -9.2%
2.39
US$29,585 		12,369 -9.2% 2.39 US$29,585
2020-09-17 2020-09-15 S Sale
ISAACS STEPHEN T

President and CEO

Executive Director
32,481 -10.4%
2.39
US$77,691 		32,481 -10.4% 2.39 US$77,691
2020-08-11 2020-08-07 S Sale
Nuyten Dimitry SA

Chief Medical Officer

Officer
3,538 -29.5%
2.55
US$9,036 		3,538 -29.5% 2.55 US$9,036
2020-08-11 2020-08-07 S Sale
Ferber Celeste

SVP, GC and Secretary

Officer
7,951 -16.2%
2.55
US$20,308 		7,951 -16.2% 2.55 US$20,308
2020-08-11 2020-08-07 S Sale
Templeman Blaine

Chief Legal Officer

Officer
7,951 -5.6%
2.55
US$20,308 		7,951 -5.6% 2.55 US$20,308
2020-02-26 2020-02-25 S Sale
van Elsas Andrea

Chief Scientific Officer

Officer
6,823 -1.5%
3.51
US$23,954 		6,823 -1.5% 3.51 US$23,954
2020-01-06 2020-01-03 S Sale
van Elsas Andrea

Chief Scientific Officer
73,311 -14.1%
1.19
US$87,108 		73,311 -14.1% 1.19 US$87,108
2019-12-16 2019-12-12 S Sale Ferber Celeste

SVP, GC and Secretary

Officer
408 -1.5%
1.16
US$475 		408 -1.5% 1.16 US$475
2019-12-16 2019-12-12 S Sale van Elsas Andrea

Chief Scientific Officer

Officer
2,192 -0.4%
1.16
US$2,550 		2,192 -0.4% 1.16 US$2,550
2019-12-16 2019-12-12 S Sale ISAACS STEPHEN T

President and CEO

Executive Director
5,897 -2.0%
1.16
US$6,860 		5,897 -2.0% 1.16 US$6,860
2019-12-16 2019-12-12 PlS Planned sale Templeman Blaine

Chief Legal Officer

Officer
1,264 -1.1%
1.16
US$1,470 		1,264 -1.1% 1.16 US$1,470
2019-09-17 2019-09-13 S Sale
van Elsas Andrea

Chief Scientific Officer
634 -0.1%
1.31
US$828 		634 -0.1% 1.31 US$828
2019-09-17 2019-09-13 S Sale
van Elsas Andrea

Chief Scientific Officer
17,959 -3.3%
1.31
US$23,451 		17,959 -3.3% 1.31 US$23,451
2019-09-17 2019-09-13 S Sale
Ferber Celeste

SVP, GC and Secretary
1,102 -3.9%
1.31
US$1,439 		1,102 -3.9% 1.31 US$1,439
Explore more

More insider trading research around Aduro Biotech Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America